Form 10-Q Voyager Therapeutics, For: Sep 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- Supermicro raises Q1 FY2027 revenue outlook on AI demand
- Dow outperforms as Wall Street rises, healthcare stocks lead gains
- Crude Inventory Fell 3.06 Million Barrels Last Week - EIA
Voyager Therapeutics (VYGR) PT Lowered to $27 at Baird
November 8, 2018 8:44 AM ESTBaird analyst Brian Skorney lowered the price target on Voyager Therapeutics (NASDAQ: VYGR) to $27.00 (from $31.00) while maintaining a Outperform rating.
The analyst commented, "After initially indicating that the Phase 2 study Voyager is about to start could be fileable, the FDA recently notified Voyager... More



